Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40271-017-0273-5 http://scihub22266oqcxt.onion/10.1007/s40271-017-0273-5 C5845075!5845075!28808991     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Patient 2018 ; 11 (2): 207-16 Nephropedia Template TP {{tp|p=28808991|t=2018. Light Chain (AL) Amyloidosis: The Journey to Diagnosis |pdf=|usr=}}{{28808991}} gab.com Text Light Chain (AL) Amyloidosis: The Journey to Diagnosis JO: Patient http://www.kidney.de/pget.php?&tw=1&pmid=28808991 #FOAvip Background: Light chain (AL) amyloidosis is a rare, complex disease associated with significant morbidity and mortality. Delays in diagnosis are common and may have detrimental consequences on patients? prognosis. Too little is known regarding the patient journey to diagnosis. Objective: The objective of this study was to describe the patient-reported journey to a correct diagnosis for AL amyloidosis. Methods: Using a mixed-methods approach, data were collected from clinician (n = 4) and patient (n = 10) interviews and a survey of community-based patients with AL amyloidosis (n = 341). Data were used to document the patient experience between the onset of symptoms and the receipt of a diagnosis. Results: Delays in diagnosis were common. Qualitative and quantitative data indicated that initial symptoms were varied and similar to other more prevalent diseases. Two themes regarding the journey to diagnosis emerged: (1) barriers to an early diagnosis; and (2) the emotional toll of the journey. Time to diagnosis was heavily influenced by how patients interpreted their initial symptoms, whether they sought early medical help, and challenges associated with making differential diagnoses. Survey results indicate that patients with primary cardiac involvement were more likely to receive a delayed diagnosis than those with primary kidney involvement. Patients described mixed emotions associated with the eventual diagnosis of AL amyloidosis. Conclusions: These data support a need for better early identification and support for patients seeking a diagnosis. Increasing clinician awareness may reduce the time to diagnosis. Additional research is needed to identify optimal diagnostic testing to reduce delays in treatment initiation and subsequent severe impacts on health. Twit Text FOAVip Light Chain (AL) Amyloidosis: The Journey to Diagnosis ????Patient http://www.kidney.de/pget.php?&tw=1&pmid=28808991 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28808991 #FOAvip English Wikipedia <ref>{{Cite pmid|28808991}}</ref> Light Chain (AL) Amyloidosis: The Journey to Diagnosis #MMPMID28808991 McCausland KL; White MK; Guthrie SD; Quock T; Finkel M; Lousada I; Bayliss MS Patient 2018[]; 11 (2): 207-16 PMID28808991show ga Background: Light chain (AL) amyloidosis is a rare, complex disease associated with significant morbidity and mortality. Delays in diagnosis are common and may have detrimental consequences on patients? prognosis. Too little is known regarding the patient journey to diagnosis. Objective: The objective of this study was to describe the patient-reported journey to a correct diagnosis for AL amyloidosis. Methods: Using a mixed-methods approach, data were collected from clinician (n = 4) and patient (n = 10) interviews and a survey of community-based patients with AL amyloidosis (n = 341). Data were used to document the patient experience between the onset of symptoms and the receipt of a diagnosis. Results: Delays in diagnosis were common. Qualitative and quantitative data indicated that initial symptoms were varied and similar to other more prevalent diseases. Two themes regarding the journey to diagnosis emerged: (1) barriers to an early diagnosis; and (2) the emotional toll of the journey. Time to diagnosis was heavily influenced by how patients interpreted their initial symptoms, whether they sought early medical help, and challenges associated with making differential diagnoses. Survey results indicate that patients with primary cardiac involvement were more likely to receive a delayed diagnosis than those with primary kidney involvement. Patients described mixed emotions associated with the eventual diagnosis of AL amyloidosis. Conclusions: These data support a need for better early identification and support for patients seeking a diagnosis. Increasing clinician awareness may reduce the time to diagnosis. Additional research is needed to identify optimal diagnostic testing to reduce delays in treatment initiation and subsequent severe impacts on health. äLight Chain (AL) Amyloidosis: The Journey to Diagnosis (epmc).pdf DeepDyve Pubget Overpricing